EntryPoint Capital’s Organogenesis Holdings ORGO Stock Holding History

EntryPoint Capital’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,988	Closed	-$166K	–	878
2025 Q4	$166K	Buy	+31,988	New	+$155K	0.06%	580
2024 Q3	–	Sell	-189,271	Closed	-$530K	–	1145
2024 Q2	$530K	Buy	+189,271	New	+$508K	0.25%	20

Other funds holding ORGO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

EntryPoint Capital's ORGO Position: Q1 2026 in Review

EntryPoint Capital sold out of Organogenesis Holdings (ORGO) in Q1 2026, closing a stake of 31,988 shares — an estimated $166K sold.

EntryPoint Capital first reported a position in ORGO in Q2 2024 and held it in 2 quarters. The position peaked at $530K in Q2 2024. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

EntryPoint Capital reported no remaining Organogenesis Holdings position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 31,988 Organogenesis Holdings shares in Q1 2026, an estimated $166K.
EntryPoint Capital first reported a position in Organogenesis Holdings in Q2 2024 and held it in 2 quarters.
EntryPoint Capital's Organogenesis Holdings position peaked at $530K in Q2 2024.
121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.